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85% (I) and 100% (II); midecamycin, 85% in both;
ampicillin, 91% (I) and 80% (II); spiramycin, 82% (I)
and 74% (II); the efficiency of ciprofloxacin was only
67% (I) and 81% (II); erythromycin, 78% (I) and 41%
(II); gentamycin, above 40% in both; trimethoprim/sul-
famethoxazole, 46% (II). The best cost-effectiveness ratio
was calculated for ampicillin, azithromycin, medecamy-
cin in both groups. The treatment with ciprofloxacin and
co-amoxiclav was less cost-effective in group I. CON-
CLUSION: The most commonly used antibiotics for
treatment of CAP were ampicillin and macrolides. This
type of treatment is adequate from medical and economic
points of view. Using of fluoroquinolones and aminogly-
cosides should be limited by gram-negative etiology.
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Adherence with HIV antiviral regimens, particularly with
the protease inhibitor (PI) is important to achieve HIV vi-
ral suppression. Complicated, multi-drug regimens can
be difficult for patients to comply with and may affect
outcomes. OBJECTIVE: To analyze adherence rates with
3-drug HIV regimens and assess the correlation of each
regimen’s adherence to HIV RNA values. METHODS:
Medication adherence and HIV RNA levels were mea-
sured in 21 patients enrolled in clinical trials in a univer-
sity-based HIV clinic. Data were collected at baseline, 2
weeks, at 4-week intervals for 24 weeks, and 8- to 12-
week intervals thereafter for up to 96 weeks. Monthly
medication adherence was calculated using pill counts.
Plasma HIV RNA was measured by standard and ultra-
sensitive RT-PCR assay. All patients were on a PI plus
2NRTI regimen. PIs included saquinavir, indinavir, and
nelfinavir. NRTIs included AZT, d4T, 3TC, and ddI. RE-
SULTS: Patient adherence with PI therapy (86%) was
found to be significantly lower (P  0.0001) than with
NRTI1 (97.7%) and NRTI2 (100.4%). Adherence rates
between NRTI1 and NRTI2 were not significantly differ-
ent. All 3 drug adherence rates were found to be nega-
tively correlated to the log of the plasma HIV RNA level
(PI R  0.430, NRTI1 R  0.181, NRTI2 R 
0.199). However, a linear regression model found that
only PI adherence was a significant predictor of HIV
RNA levels. CONCLUSION: This study indicates that
adherence with the PI regimen was significantly lower
than with nucleoside analog compounds. The results also
indicate that only adherence with the PI was a significant
predictor of virologic response.
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Assessing the impact of HIV infection and its treatment
on patient-reported health outcomes, such as health-
related quality of life (HRQOL), is critically important.
Therefore, evidence for the validity of HRQOL instru-
ments in persons with HIV is essential in evaluating the
appropriateness of their use. OBJECTIVES: The purpose
of this study was to evaluate the ability of the SF-12’s
mental and physical component summary scores (i.e.,
PCS-12 and MCS-12) to discriminate between HIV-
infected subjects in pre-defined disease severity groups
based on clinical indicator status. METHODS: This
cross-sectional study involved the collection of clinical
data (i.e., CD4 cell counts, HIV-1 viral load) from pa-
tients’ medical records and self-completion of the SF-12
at two HIV specialty clinics. The relationships between
the following variables were examined: PCS-12 scores,
MCS-12 scores, CD4 cell counts, and plasma HIV-1 viral
load. In addition, the ability of the SF-12 summary scores
to discriminate between subjects stratified by disease se-
verity (i.e., CD4  200 vs. CD4  200; viral load 
30,000 vs. viral load  30,000) was assessed. RESULTS:
Data were collected from 478 subjects. Statistically sig-
nificant correlations were found between the PCS-12 and
CD4 cell counts (r  0.208, P  0.000) and viral loads
(r  0.131, P  0.01). There were no statistically sig-
nificant correlations found between the MCS-12 and ei-
ther of the clinical indicators. The scores from the PCS-12
were able to discriminate between groups of subjects
stratified by disease severity based on CD4 cell counts
(P  0.000) and viral loads (P  0.01). CONCLUSIONS:
These findings provide evidence that, although the SF-12
is a brief, generic health status measure, it can be a useful
means of monitoring HIV-related disease status from the
patient’s perspective.
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Although the impact of diseases and treatments on qual-
ity of life has become a major concern in the evaluation
of health care interventions, it has been seldom evaluated
for acute respiratory tract infections (RTI). OBJECTIVE:
To measure the quality of life in adults treated for com-
munity acquired RTI. METHODS: Patients aged 18
were recruited by community pharmacists. They were
considered for inclusion if they reported being treated for
